A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma.

@article{Bhatt2010AP2,
  title={A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma.},
  author={Rupal S. Bhatt and Jaime R. Merchan and Robert Y. Parker and Hua-Kang Wu and Liang Zhang and Virginia J. Seery and John V. Heymach and Michael B. Atkins and David B. Mcdermott and Vikas P Sukhatme},
  journal={Cancer},
  year={2010},
  volume={116 7},
  pages={1751-6}
}
BACKGROUND : Tumor angiogenesis has been associated with a poor prognosis in patients with metastatic melanoma (MM). Microtubule stabilizers and cyclooxygenase 2 (COX-2) inhibitors, alone and in combination, have produced inhibitory effects on endothelial cells and tumor angiogenesis. Angiogenesis, which is the growth of new blood vessels, is necessary for tumor growth and progression. Thus, the authors tested the safety and efficacy of a low dose of paclitaxel and celecoxib in patients with MM… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 34 extracted citations

Similar Papers

Loading similar papers…